Croda Inc was established in 1950 in New York City. Our headquarters today are in Princeton, New Jersey, and we have manufacturing sites in New Castle (Delaware), Mill Hall (Pennsylvania), Lamar (Pennsylvania), Salinas (California), and Alabaster (Alabama). We also have three sales hubs at Princeton (New Jersey), Chino Hills (California) and Urbandale (Iowa).
More than 950 employees work in manufacturing, sales, marketing, and R&D. Outside day-to-day operations, sites and employees regularly come together to give back to the community through the Croda 1% Club and community engagement.
We have three innovation centers in the U.S. Our New Jersey headquarters R&D labs focus on applications for all markets and new product development for Personal Care. The Griffin Centre in Delaware focuses on product development in Crop Care. Our Incotec Innovation Centre in Iowa provides agricultural products and solutions for Seed Enhancement.
At Atlas Point, we are converting to renewable energy initiatives, including the use of onsite solar panels and combined heat and power (CHP) units powered by landfill gas. In Since 2021, we use 100% renewable electricity at the facility. Atlas Point is also home to our ECO Range, which manufactures 100% bio-based surfactants, the first of their kind in the USA.
The Croda Mill Hall manufacturing facility is certified to the EXCiPACT GMP Certification Standard for our excipient product offerings and the EFfCI (European Federation for Cosmetic Ingredients) GMP Guide for personal care offerings. The site uses wind-sourced electricity, and we are pursuing the potential purchase of renewable fuels to further reduce emissions.
Four miles from Mill Hall, the Lamar site is in the development stage, targeted for completion in 2025. The site will increase Croda’s U.S. manufacturing capacity of ingredients for lipid systems used in novel therapeutic drugs, like mRNA vaccines. The location is supplied with renewable, green electricity with future growth plans for a 15-20 acre solar array to support carbon neutrality at Lamar.
Incotec North America provides seed coating technologies that enable a reduction in the use of crop protection products of up to 90%. At both our Incotec Innovation Centre and manufacturing site we use green energy.
Avanti Polar Lipids is focused on developing innovative lipid-based products of unparalleled purity to address specific medical challenges that are not resolved by current technology or drug products.
Croda, Inc. North America supports several business sectors. To learn more about our divisions, or to contact us with a sales inquiry, see below. Each page offers a chat function, answered during normal business hours (EST). If we are not online at the time of your inquiry, an email icon will display. Contact Us electronic forms are also available.
Croda Inc and Sederma Inc (Princeton)
777 Scudders Mill Road, Building 2, Suite 200
Tel: +1 609 212 2500
Croda Inc (Mill Hall)
8 Croda Way
Croda Inc (Lamar)
88 Heckmans Gap Rd
Croda Inc (Chino Hills)
5871 Pine Avenue, Suite 220
1293 Harkins Road
4725 121st Street
700 Industrial Park Drive
Tel: +1 205 663 2494
2550 Acton Road
Croda, Inc. is complying with the Federal Government’s Transparency in Coverage rule by making public machine-readable files containing pricing information available to the public. These recordable files include negotiated rates for in-network providers and allowed amounts and historical billed charges for out-of-network providers for our employee health plans.
Acquisition of Solus Biotech expands fast growth Beauty Actives business in Asia
6 February 2023: Croda International Plc (‘Croda’) announces that it has agreed to acquire Solus Biotech (‘Solus’), a global leader in premium, biotechnology-derived beauty actives.Read more
Launch of first report on biotechnology opportunities in the personal care market
27 September 2022: The “Biotechnology: personal care market report” is the first in a series from Croda which aim to help other forward-thinking companies leverage the opportunities offered by...Read more
UK Government to support expansion of Croda's lipid systems manufacturing facility
31 March 2022: This investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines.Read more